Sands Capital Management
ALXN

Sands Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sands Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,766,636
Closed -$269M – 75
2018
Q4 		$269M Sell
2,766,636
-198,591
-7% -$23.5M 0.96% 33
2018
Q3 		$412M Sell
2,965,227
-259,112
-8% -$32.5M 1.17% 27
2018
Q2 		$400M Sell
3,224,339
-217,269
-6% -$25.4M 1.15% 29
2018
Q1 		$384M Sell
3,441,608
-1,111,487
-24% -$133M 1.13% 30
2017
Q4 		$545M Sell
4,553,095
-222,852
-5% -$27.1M 1.65% 23
2017
Q3 		$670M Sell
4,775,947
-1,570,127
-25% -$213M 2.01% 18
2017
Q2 		$772M Buy
6,346,074
+1,110,444
+21% +$129M 2.32% 17
2017
Q1 		$635M Sell
5,235,630
-349,638
-6% -$45.1M 1.99% 19
2016
Q4 		$683M Buy
5,585,268
+339,516
+6% +$41.5M 2.38% 17
2016
Q3 		$643M Buy
5,245,752
+370,994
+8% +$47.8M 1.89% 22
2016
Q2 		$569M Sell
4,874,758
-337,121
-6% -$47.8M 1.76% 23
2016
Q1 		$726M Sell
5,211,879
-844,883
-14% -$124M 2.14% 21
2015
Q4 		$1.16B Sell
6,056,762
-323,095
-5% -$56.4M 2.98% 15
2015
Q3 		$998M Sell
6,379,857
-139,689
-2% -$25.5M 2.79% 16
2015
Q2 		$1.18B Buy
6,519,546
+1,315,250
+25% +$227M 2.9% 16
2015
Q1 		$902M Sell
5,204,296
-63,607
-1% -$11.5M 2.15% 22
2014
Q4 		$975M Sell
5,267,903
-43,585
-0.8% -$8.08M 2.32% 20
2014
Q3 		$881M Buy
5,311,488
+31,706
+0.6% +$5.21M 2.19% 21
2014
Q2 		$825M Buy
5,279,782
+11,364
+0.2% +$1.79M 2.08% 23
2014
Q1 		$801M Sell
5,268,418
-2,102,183
-29% -$334M 2.09% 24
2013
Q4 		$979M Sell
7,370,601
-169,804
-2% -$20.4M 2.56% 20
2013
Q3 		$876M Sell
7,540,405
-884,162
-10% -$97M 2.44% 19
2013
Q2 		$777M Buy
+8,424,567
New +$812M 2.62% 18

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management's ALXN Position: Q1 2019 in Review

Sands Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 2,766,636 shares — an estimated $269M sold.

Sands Capital Management first reported a position in ALXN in Q2 2013 and held it in 23 quarters. The position peaked at $1.18B in Q2 2015. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Sands Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Sands Capital Management sold 2,766,636 Alexion Pharmaceuticals shares in Q1 2019, an estimated $269M.
  • Sands Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Sands Capital Management's Alexion Pharmaceuticals position peaked at $1.18B in Q2 2015.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Sands Capital Management's 13F filing for Q1 2019, filed 15 May 2019.